About Dr Sermorelin

What this site is

Dr Sermorelin is an independent editorial project that publishes summaries of the peer-reviewed research literature on Sermorelin (GHRH(1-29)). We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The site reads the literature the way the design reads the coast — slowly, one wide finding at a time, with a lot of open water around each claim. Every quantitative statement maps to a study you can check in the reference list.

On the name

The "Dr" in Dr Sermorelin is editorial framing, not a clinical claim. It marks the position this publisher occupies relative to the literature — a careful, clinical-context reading of who studies the growth-hormone axis and what the qualified-investigator research shows — not a doctor, a doctor's office, or a service that diagnoses, treats, or prescribes. There is no physician, clinic, pharmacy, or consultation behind this site, and none is implied. The modifier is a reading posture; the substance is a literature digest.

How we handle the evidence

We lead with what was measured and attribute it to the study that measured it. Where the data are precise — a 14-day GH/IGF-1 reversal in older men ^[5], a pediatric height-velocity change ^[2], a ~10-12 minute half-life ^[3] — we say so plainly. Where the data are thin — durable adult anti-aging benefit, long-term adult safety — we mark the gap rather than paper over it ^[9]. We keep the analog attributions honest: results generated with tesamorelin are labeled as the analog's, not native sermorelin's ^[10]. We describe research findings; we do not give human dosing, and we name no products, vendors, or brands.

We also try to get the regulatory facts right, because they are the ones most often garbled. Sermorelin was a real FDA-approved drug, withdrawn from the US market in 2008 for commercial reasons and now compounded — not "never approved," not "currently approved," and not banned for safety. We state that history the same way every time, and we note the WADA sport-prohibition status where it is relevant. The material these pages discuss is research-grade sermorelin supplied for laboratory research, which is why nothing here reads as a medicine to self-administer.

Independence and corrections

This project is independent. It is funded as an editorial publication, not by any seller of sermorelin or any related compound, and it carries no storefront, price list, or order path. When the literature is uncertain, we would rather say so than imply a confidence the studies do not support — the empty long-term-adult-safety line stays visibly empty.

The published record changes as new studies appear, and we treat the digest as revisable. If you find a citation that should be updated, a finding we have characterized incorrectly, or a newer source that sharpens the picture, the contact page is the place to flag it. Corrections that hold up against the source get made.